PMC:6562565 / 67848-69019 JSONTXT

{"project":"MyTest","denotations":[{"id":"31244820-29802128-35366407","span":{"begin":28,"end":31},"obj":"29802128"},{"id":"31244820-16916931-35366408","span":{"begin":92,"end":94},"obj":"16916931"},{"id":"31244820-16916931-35366409","span":{"begin":199,"end":201},"obj":"16916931"},{"id":"31244820-29802128-35366410","span":{"begin":203,"end":206},"obj":"29802128"},{"id":"31244820-16916931-35366411","span":{"begin":253,"end":255},"obj":"16916931"},{"id":"31244820-28165340-35366412","span":{"begin":454,"end":457},"obj":"28165340"},{"id":"31244820-29923026-35366413","span":{"begin":459,"end":462},"obj":"29923026"},{"id":"31244820-16916931-35366414","span":{"begin":497,"end":499},"obj":"16916931"},{"id":"31244820-29802128-35366415","span":{"begin":501,"end":504},"obj":"29802128"},{"id":"31244820-28165340-35366416","span":{"begin":541,"end":544},"obj":"28165340"},{"id":"31244820-20179192-35366417","span":{"begin":546,"end":549},"obj":"20179192"},{"id":"31244820-29923026-35366418","span":{"begin":551,"end":554},"obj":"29923026"},{"id":"31244820-29802128-35366419","span":{"begin":556,"end":559},"obj":"29802128"},{"id":"31244820-28165340-35366420","span":{"begin":708,"end":711},"obj":"28165340"},{"id":"31244820-29923026-35366421","span":{"begin":843,"end":846},"obj":"29923026"},{"id":"31244820-29923026-35366422","span":{"begin":1086,"end":1089},"obj":"29923026"},{"id":"31244820-28165340-35366423","span":{"begin":1156,"end":1159},"obj":"28165340"},{"id":"31244820-29923026-35366424","span":{"begin":1161,"end":1164},"obj":"29923026"},{"id":"31244820-29802128-35366425","span":{"begin":1166,"end":1169},"obj":"29802128"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Similarly, A2AR deficiency (402) or siRNA-mediated suppression of A2AR and A2BR expression (38) on the surface of adoptively transferred T cells leads to enhanced prevention of metastatic spreading (38, 402) and improved survival of tumor-bearing mice (38). Several groups have validated these observations by demonstrating that ACT and concomitant administration of A2AR antagonists is superior to single treatments in terms of decreasing tumor growth (135, 396), hindering metastasis formation (38, 402) and ultimately improving survival (135, 388, 396, 402). Interestingly, others claim that A2AR antagonism improves the efficacy of adoptively transferred CAR+ T cells only if PD1 ICB is co-administered (135). In terms of mechanisms, concomitant A2AR antagonism not only increases intra-tumoral presence of adoptively transferred T cells (396) but also elevates their activation status. In particular, when A2AR antagonists were co-administered, tumor-derived, adoptively transferred or endogenous CD44+ CD8+ T cells, exhibit heightened expression levels of T-bet, 4-1BB, and CD69 (396) while demonstrating increased capacity to produce IFNγ and TNFα (135, 396, 402)."}

{"project":"TEST0","denotations":[{"id":"31244820-28-35-3850555","span":{"begin":28,"end":31},"obj":"[\"29802128\"]"},{"id":"31244820-92-98-3850556","span":{"begin":92,"end":94},"obj":"[\"16916931\"]"},{"id":"31244820-199-205-3850557","span":{"begin":199,"end":201},"obj":"[\"16916931\"]"},{"id":"31244820-203-210-3850558","span":{"begin":203,"end":206},"obj":"[\"29802128\"]"},{"id":"31244820-237-243-3850559","span":{"begin":253,"end":255},"obj":"[\"16916931\"]"},{"id":"31244820-196-203-3850560","span":{"begin":454,"end":457},"obj":"[\"28165340\"]"},{"id":"31244820-201-208-3850561","span":{"begin":459,"end":462},"obj":"[\"29923026\"]"},{"id":"31244820-231-237-3850562","span":{"begin":497,"end":499},"obj":"[\"16916931\"]"},{"id":"31244820-235-242-3850563","span":{"begin":501,"end":504},"obj":"[\"29802128\"]"},{"id":"31244820-234-241-3850564","span":{"begin":541,"end":544},"obj":"[\"28165340\"]"},{"id":"31244820-236-243-3850565","span":{"begin":546,"end":549},"obj":"[\"20179192\"]"},{"id":"31244820-227-234-3850566","span":{"begin":551,"end":554},"obj":"[\"29923026\"]"},{"id":"31244820-232-239-3850567","span":{"begin":556,"end":559},"obj":"[\"29802128\"]"},{"id":"31244820-146-153-3850568","span":{"begin":708,"end":711},"obj":"[\"28165340\"]"},{"id":"31244820-129-136-3850569","span":{"begin":843,"end":846},"obj":"[\"29923026\"]"},{"id":"31244820-195-202-3850570","span":{"begin":1086,"end":1089},"obj":"[\"29923026\"]"},{"id":"31244820-228-235-3850571","span":{"begin":1156,"end":1159},"obj":"[\"28165340\"]"},{"id":"31244820-233-240-3850572","span":{"begin":1161,"end":1164},"obj":"[\"29923026\"]"},{"id":"31244820-233-240-3850573","span":{"begin":1166,"end":1169},"obj":"[\"29802128\"]"}],"text":"Similarly, A2AR deficiency (402) or siRNA-mediated suppression of A2AR and A2BR expression (38) on the surface of adoptively transferred T cells leads to enhanced prevention of metastatic spreading (38, 402) and improved survival of tumor-bearing mice (38). Several groups have validated these observations by demonstrating that ACT and concomitant administration of A2AR antagonists is superior to single treatments in terms of decreasing tumor growth (135, 396), hindering metastasis formation (38, 402) and ultimately improving survival (135, 388, 396, 402). Interestingly, others claim that A2AR antagonism improves the efficacy of adoptively transferred CAR+ T cells only if PD1 ICB is co-administered (135). In terms of mechanisms, concomitant A2AR antagonism not only increases intra-tumoral presence of adoptively transferred T cells (396) but also elevates their activation status. In particular, when A2AR antagonists were co-administered, tumor-derived, adoptively transferred or endogenous CD44+ CD8+ T cells, exhibit heightened expression levels of T-bet, 4-1BB, and CD69 (396) while demonstrating increased capacity to produce IFNγ and TNFα (135, 396, 402)."}

{"project":"2_test","denotations":[{"id":"31244820-29802128-35366407","span":{"begin":28,"end":31},"obj":"29802128"},{"id":"31244820-16916931-35366408","span":{"begin":92,"end":94},"obj":"16916931"},{"id":"31244820-16916931-35366409","span":{"begin":199,"end":201},"obj":"16916931"},{"id":"31244820-29802128-35366410","span":{"begin":203,"end":206},"obj":"29802128"},{"id":"31244820-16916931-35366411","span":{"begin":253,"end":255},"obj":"16916931"},{"id":"31244820-28165340-35366412","span":{"begin":454,"end":457},"obj":"28165340"},{"id":"31244820-29923026-35366413","span":{"begin":459,"end":462},"obj":"29923026"},{"id":"31244820-16916931-35366414","span":{"begin":497,"end":499},"obj":"16916931"},{"id":"31244820-29802128-35366415","span":{"begin":501,"end":504},"obj":"29802128"},{"id":"31244820-28165340-35366416","span":{"begin":541,"end":544},"obj":"28165340"},{"id":"31244820-20179192-35366417","span":{"begin":546,"end":549},"obj":"20179192"},{"id":"31244820-29923026-35366418","span":{"begin":551,"end":554},"obj":"29923026"},{"id":"31244820-29802128-35366419","span":{"begin":556,"end":559},"obj":"29802128"},{"id":"31244820-28165340-35366420","span":{"begin":708,"end":711},"obj":"28165340"},{"id":"31244820-29923026-35366421","span":{"begin":843,"end":846},"obj":"29923026"},{"id":"31244820-29923026-35366422","span":{"begin":1086,"end":1089},"obj":"29923026"},{"id":"31244820-28165340-35366423","span":{"begin":1156,"end":1159},"obj":"28165340"},{"id":"31244820-29923026-35366424","span":{"begin":1161,"end":1164},"obj":"29923026"},{"id":"31244820-29802128-35366425","span":{"begin":1166,"end":1169},"obj":"29802128"}],"text":"Similarly, A2AR deficiency (402) or siRNA-mediated suppression of A2AR and A2BR expression (38) on the surface of adoptively transferred T cells leads to enhanced prevention of metastatic spreading (38, 402) and improved survival of tumor-bearing mice (38). Several groups have validated these observations by demonstrating that ACT and concomitant administration of A2AR antagonists is superior to single treatments in terms of decreasing tumor growth (135, 396), hindering metastasis formation (38, 402) and ultimately improving survival (135, 388, 396, 402). Interestingly, others claim that A2AR antagonism improves the efficacy of adoptively transferred CAR+ T cells only if PD1 ICB is co-administered (135). In terms of mechanisms, concomitant A2AR antagonism not only increases intra-tumoral presence of adoptively transferred T cells (396) but also elevates their activation status. In particular, when A2AR antagonists were co-administered, tumor-derived, adoptively transferred or endogenous CD44+ CD8+ T cells, exhibit heightened expression levels of T-bet, 4-1BB, and CD69 (396) while demonstrating increased capacity to produce IFNγ and TNFα (135, 396, 402)."}